1. In Vitro Susceptibility of Clostridium difficile Clinical Isolates from a Multi-Institutional Outbreak in Southern Québec, Canada
- Author
-
François Lamothe, Anne-Marie Bourgault, Vivian G. Loo, and Louise Poirier
- Subjects
Cefotaxime ,Microbial Sensitivity Tests ,Meropenem ,Disease Outbreaks ,Microbiology ,Levofloxacin ,Drug Resistance, Bacterial ,polycyclic compounds ,Humans ,Medicine ,heterocyclic compounds ,Pharmacology (medical) ,Enterocolitis, Pseudomembranous ,Pharmacology ,Cross Infection ,Clostridioides difficile ,business.industry ,Quebec ,Clindamycin ,biochemical phenomena, metabolism, and nutrition ,Clostridium difficile ,bacterial infections and mycoses ,Anti-Bacterial Agents ,Ciprofloxacin ,Metronidazole ,Infectious Diseases ,Susceptibility ,Vancomycin ,business ,medicine.drug - Abstract
Clostridium difficile isolates from a 2004 outbreak in Québec, Canada, were all found to be susceptible to metronidazole, vancomycin, rifampin, and meropenem but resistant to bacitracin, cefotaxime, ciprofloxacin, and levofloxacin, and most (>80%) were resistant to ceftriaxone, clarithromycin, gatifloxacin, and moxifloxacin. The predominant NAP1 isolates were susceptible to clindamycin, while the NAP2 isolates were resistant.
- Published
- 2006
- Full Text
- View/download PDF